drug discovery and development

In this webinar series, learn about 21 CFR Part 11 regulations for flow cytometry in drug discovery. Learn what software and instruments can help you comply.

Although chromatography resins are usually thought of as tools to purify medicines, groundbreaking treatments now utilize resin beads as an integral component of the therapy itself. These therapies are essential for treating certain cancers and inflammatory disorders.

Translational research bridges the gap between scientific discoveries and real-world applications, transforming scientific breakthroughs into life-changing therapies. Success in this endeavor hinges on several factors, including collaboration between scientists and clinicians. A notable example of this is the approval of Zolgensma, a gene therapy for spinal muscular atrophy (SMA), which marked a significant milestone in the field of translational research.

The differences between us are what makes life interesting, and diversity in a group that shares a common goal can lead to many benefits. Here we examine the similarities and differences between researchers using flow cytometry for academic research and those using it for drug discovery. We outline the challenges they face and learn that they share a common goal as well as a common solution.

The Pioneer Platform features one of the largest functional antibody libraries available, utilizing SpyLock technology for rapid prototyping and screening of hundreds of bispecific antibodies, and TrailBlazer technology for efficient antibody format conversion. Together, these services provide a comprehensive and streamlined solution for researchers seeking to develop innovative biotherapeutic therapies.

Many researchers learn flow cytometry in academia, but find new challenges in the commercial sector. In this webinar, learn about regulatory issues and more.

The realm of druggable targets has expanded significantly with the advent of mRNA therapeutics. Scientists require exceptional accuracy and confidence to adequately characterize these therapeutics and their anticipated effects. To this end, Droplet Digital PCR (ddPCR) technology has proven invaluable. With unparalleled precision and absolute quantification, Droplet Digital PCR is revolutionizing the field of mRNA therapeutic development and manufacturing.

Immunotherapy has revolutionized cancer treatment, yet the drug discovery process to develop new biotherapeutic antibodies remains arduous. However, significant advances in antibody technology such as phage display have enabled fully human antibodies to be developed from animal-free libraries for just about any antigen.

Inadequate quality control assays shouldn’t limit cell and gene therapy applications. Instead, quantifying the potency of cell and gene therapies is essential for successful therapeutics. In this article, we describe multiple leading potency assays developed using Droplet Digital PCR (ddPCR) technology, including an assay that quantifies transgene integration and expression in one step.

Disparate systems, distributed teams, and overly complex technologies are a recipe for inefficiency in research and development (R&D) laboratories, especially in drug development. With the pressure to meet challenging deadlines and strict regulations, it is easy for working practices to become disconnected. To improve the efficiency, accuracy, and consistency of data generation, acquisition, and management, R&D organizations are looking to streamline their lab practices by investing in technologies that automate data generation, accelerate data collection speed and storage, and enhance the quality and reliability of the information produced. Lab automation presents exciting opportunities for future research, promising novel advances in machine learning and artificial intelligence (AI), liquid handling robotics, and cloud-based data workflows.